By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug Administration granted accelerated approval for tovorafenib (Ojemda, Day One Biopharmaceuticals, Inc.) for relapsed or refractory pediatric low-grade
Hematologists & Oncologists from Across Country Met to Discuss Latest Updates in Care On August 4-5, 2023, the Binaytara Foundation held the Seattle Cellular Therapy Summit. This annual conference gathers leading
MoreX-7/7 trial: Alternative fixed dosing of capecitabine associated with similar efficacy with better safety profile By Drs. Arya Mariam Roy & Shipra Gandhi Roswell Park Comprehensive Cancer Center The approved
MoreBy Dr. Aakash Desai Mayo Clinic KEYNOTE-789: No Significant Efficacy Benefit with Addition of Pembrolizumab to Chemotherapy in TKI-Resistant, EGFR-Mutated Metastatic Nonsquamous NSCLC Key Points: The KEYNOTE-789 trial did not
MoreBy Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Hodgkin’s lymphoma (HL) has had an exciting and interesting recent history with the introduction of brentuximab (BV) +AVD (Adriamycin, vinblastine,
MoreImetelstat in low-risk MDS for transfusion independence By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center ASCO presented an anticipated update to imetelstat in MDS. In the phase
MoreBy Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Low-risk MDS had many exciting updates, starting with the COMMANDS trial. This study is an open-label randomized phase 3 trial
MoreAuthor: Lei Deng, MD Roswell Park Comprehensive Cancer Center Live report from ASCO23, Chicago, IL June 6, 2023 LBA9005 Tumor Treating Field (TTFields) therapy with standard of care (SOC) in
MoreAuthor: Lei Deng, MD Roswell Park Comprehensive Cancer Center Live report from ASCO23, Chicago, IL June 6, 2023 9002 Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations:
MorePalbociclib after progression on Palbociclib in HR-positive HER2-negative breast cancer does not show improvement in progression-free survival By Dr. Malak Alharbi of Roswell Park Comprehensive Cancer Center CDK4/6i plus endocrine
MoreBy Dr. Arya Miriam Roy & Dr. Shipra Gandhi of Roswell Park Comprehensive Cancer Center The CDK 4/6 inhibitors with endocrine therapy are the current standard of care for first-line treatment
More